Fosun Pharma's mRNA COVID-19 vaccine is approved for emergency use in Hong Kong
The mRNA COVID-19 vaccine was obtained by Fosun Pharma signed a license agreement with BioNTech SE of Germany on March 13, 2020. Fosun Pharma has the exclusive rights to develop and commercialize mRNA COVID-19 vaccine in Mainland China, Hong Kong, Macau and Taiwan.
BioNTech's mRNA vaccine has reached all the main efficacy endpoints in the global phase III clinical trial. It is 95% effective in preventing the new coronavirus and is more than 94% effective in adults over 65 years old. At all ages, genders, Race and ethnicity demographically show consistent effectiveness.
On January 26, 2021, Fosun Pharma announced that the mRNA Covid-19 vaccine has become the first Covid-19 vaccine approved by the Hong Kong Food and Health Bureau for emergency use in Hong Kong, and will be used for supply under the Hong Kong Government's Covid-19 vaccination plan. Distribution and application etc.
2-Amino-5-chlorobenzotrifluoride, CAS: 445-03-4
4-(Trifluoromethoxy)benzoyl chloride, CAS: 36823-88-8
1,1'-Thiocarbonyldiimidazole, CAS: 6160-65-2
Methyl 3-amino-2-fluorobenzoate, CAS: 1195768-18-3
2-Amino-5-fluorophenol, CAS: 53981-24-1
(3R)-3-fluoropyrrolidine hydrochloride, CAS: 136725-55-8